153 results about "Intracellular ferritin" patented technology

A method of forming mono-disperse iron-oxide core metal shell nanoparticles is disclosed. Particle size of the oxide core seeds is controlled and capped seeds are formed. The capping layer is desorbed by a thermally activated process and metal such as gold is chemically deposited on the core seeds in situ. This process can be repeated to produce multi-metal or different metal shells. A second capping layer is applied on the core/shell composite nanoparticles. In another step, the particles are sized by centrifuging to obtain a tightly controlled and narrow particle size distribution. The water-dispersibility of the particles is achieved by a thiol exchange reaction on the gold shell of the core/shell nanoparticles or by deposition of gold on ferritin-derived iron oxide cores in aqueous solution. Mono and multilayer thin films are assembled on different substrates using the core/shell particles and linking molecules.

The invention provides a ferritin nanoparticle carrier for preparing a vaccine, and also provides a vaccine based on the ferritin nanoparticle carrier, and a preparation method thereof. The ferritin nanoparticle carrier is formed by self-assembling ferritin with fuse-expressed SpyCatcher, or is formed by self-assembling ferritin with fuse-expressed SpyTag, the vaccine further comprises an antigenwith fuse-expressed SpyTag when the nanoparticle carrier is formed by self-assembling the ferritin with fuse-expressed SpyCatcher, and the vaccine further comprises an antigen with fuse-expressed SpyCatcher when the nanoparticle carrier is formed by self-assembling the ferritin with fuse-expressed SpyTag, wherein the ferritin is covalently linked to the antigen by a SpyCatcher-SpyTag interaction.

The invention provides a fusion ferritin protein wherein a ferritin heavy chain polypeptide is fused to a peptide, wherein the peptide is fused to the C-terminal end of the ferritin heavy chain; and the peptide includes at least a portion of a Mms6 protein sequence and at least one heterologous amino acid at its N-terminal end. The invention further provides methods of use of the ferritin fusion protein for Magnetic Resonance Imaging.

The present invention provides an antineoplastic drug with ferritin as a carrier and a preparation method thereof, the method comprising the following steps: preparing ferritin; performing high pressure treatment on a mixed solution of ferritin and antineoplastic drug at a pressure of 200-800MPa6 ‑20h; the product after high pressure treatment is separated and purified to obtain an anti-tumor drug with ferritin as a carrier. The method of the present invention can not only increase the loading ratio of drugs, the yield of drug-loaded ferritin is close to 100%, but also can completely recover free unloaded anti-tumor drugs, improve production efficiency, reduce production costs, and is suitable for large-scale industrial production .

The invention discloses a preparation method of an FER (Ferritin) zeolite molecular sieve with high silica-alumina ratio. The method comprises the following steps of: first, dissolving an aluminum source in a mixed liquid of sodium hydroxide, alkali and alkaline earth salt of weak acid; after adding the aluminum source, stirring and dispersing for a period of time by strong magnetic force at room temperature; mixing uniformly dispersed aluminum source and aluminum source liquid at room temperature to form glue; adding the FER zeolite molecular sieve as crystal seeds; after uniformly stirring and mixing at room temperature by strong force, transferring to a reaction crystallization kettle; crystallizing for 0.5-3 days by 130-170 DEG C microwave; and conventionally, filtering, washing and drying to obtain the sieve. According to the preparation method provided by the invention, expensive organic amine is not used as a structure-directing agent, and the FER zeolite molecular sieve is used as a crystal seed for microwave crystallization in an inorganic system with low alkalinity and high salinity. The crystallization degree and purity of products prepared are high, the silica-alumina ratio is easy to regulate, the synthetic cost is low, the environmental-pollution less, and the method is convenient for industrial large-scale production.

Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL-1-beta, Brain-Derived Nerotrophic Factor, Apolipoprotein A1, Serum Amyloid P, Growth Hormone, Beta-2 microglobulin, Lipoprotein (a), MMP-9, Thyroid Stimulating hormone, alpha-2 Macroglobulin, Complement 3, IL-7, Leptin, and IL-6. Kits containing reagents to assist in the analysis of fluid samples are also described.

Methods and compositions for treating an iron disorder in a patient are presented, including methods for delivering a therapeutically effective amount of iron to the brain. Iron disorders that may be treated by these methods include iron deficiency disorders and iron overload disorders. A recombinant yeast expressing human H-ferritin and a composition for treating an iron disorder comprising this recombinant yeast are also presented.

A decontamination system uses magnetic molecules having ferritin cores to selectively remove target contaminant ions from a solution. The magnetic molecules are based upon a ferritin protein structure and have a very small magnetic ferritin core and a selective ion exchange function attached to its surface. Various types of ion exchange functions can be attached to the magnetic molecules, each of which is designed to remove a specific contaminant such as radioactive ions. The ion exchange functions allow the magnetic molecules to selectively absorb the contaminant ions from a solution while being inert to other non-target ions. The magnetic properties of the magnetic molecule allow the magnetic molecules and the absorbed contaminant ions to be removed from solution by magnetic filtration.

The invention discloses a method for separating purified ferritins from biological tissues or engineering bacteria. The method comprises the following steps of: performing mechanical lapping or ultrasonication by taking ferritin-enriched animal tissues or organs or engineering bacteria which are collected by fermenting and contain recombination ferritin genes as a raw material for extracting ferritins to obtain uniform serum, performing heat denaturation treatment on the filtered uniform serum in water with the temperature between 70 DEG C and 75 DEG C for 20 minutes, and centrifugally extracting supernatant to obtain a crude protein solution; performing dialysis equilibrium on the obtain crude protein solution, performing nickel column affinity chromatography and eluting by using 250 mM of competitive imidazole buffer solution to obtain electrophoretically pure ferritins; and further performing sepHarose 6B molecular sieve exclusion chromatography on the ferritins to obtain monomer ferritins and polymer ferritins which are separated from each other. By adopting the method, electrophoretically pure ferritins can be obtained by directly performing nickel column affinity chromatography in the absence of tag, so that purifying steps of the ferritins are greatly eliminated.

An isolated ferritin fusion protein is provided in which ferritin is fused with a protein or peptide capable of being fused to ferritin without interfering with the polymeric self-assembly of the resulting fusion protein, and the protein may be of the endocapsid form when fused at the C terminus or an exocapsid form when fused at the N terminus. These fusion proteins may self-assemble into a variety of useful higher polymeric forms, e.g., capsid or other polymeric aggregate, and they are advantageous in that they are useful in a variety of applications, including human and veterinary vaccines and therapeutics, blood substitutes, image contrast agents, metal chelating agents, gelling agents, protein purification platforms, and therapeutic receptor-binding proteins.

The invention provides a bionic binary cooperative nano-carrier as well as a preparation method and an application thereof. The bionic binary cooperative nano-carrier comprises an erythrocyte membrane, glucose oxidase, iron-supporting ferritin nano-particles and a photosensitizer, wherein the glucose oxidase and the iron-supporting ferritin nano-particles are coated with the erythrocyte membrane,and the photosensitizer is embedded into the surface of the erythrocyte membrane or entrapped by the erythrocyte membrane. Chain stimulative responsibility coordination of tumor hunger therapy and chemical kinetic therapy is realized, two enzymes are conveyed to a target site of an organism with the carrier on the basis of biocompatibility of the erythrocyte membrane and tumor targeting of targeting molecules, accurate administration is realized by membrane rupture based on 808 nm near-infrared light illumination in the tumors, the problem of drug resistance is solved effectively, furthermore,systemic toxicity caused by drug application is remarkably reduced, and damage to other normal tissue in an in-vivo circulation process is prevented effectively. The invention further provides the preparation method of the bionic binary cooperative nano-carrier. The bionic binary cooperative nano-carrier and the preparation method have good application prospect.

The invention relates to a serum ferritin content detection kit. The serum ferritin content detection kit has the advantages of being high in accuracy, good in anti-jamming capability and the like. The serum ferritin content detection kit contains a reagent R1, a reagent R2 and a standard ferritin product. The reagent R1 is prepared from, by weight, 5-50 mM of buffer solution, 100-200 mM of electrolyte, 0.5-3% of sealing agent, 0.05-0.5% of surfactant, 0.05-0.5% of preservative and 0.5-5% of coagulant. The reagent R2 is prepared from, by weight, 5-50 mM of buffer solution, 100-200 mM of electrolyte, 0.5-3% of sealing agent, 3-10 mM of metal chelate agent, 0.05-0.5% of surfactant, 0.05-0.5 % preservative, 3-10% protective agent and 0.05-0.5% of ferritin monoclonal antibody F (ab') 2 fragment sensitized nano latex particles.

The invention discloses a method for preparing a gene recombinant human ferritin light chain. The method comprises the following steps of: amplifying a coding genetic sequence of a ferritin light chain (Ferritin L) in human fresh complete blood cells by PCR, cloning the amplified coding genetic sequence into an expression vector pET-30a by enzyme digestion and connection, transforming E.coli BL21 (DE3), identifying a positive cloning colony, performing induction expression on the Ferritin L by IPTG, and analyzing the antigenicity of the Ferritin L by using Westernblot. The method successfully constructs the prokaryotic expression vector of the FTL, and obtains the pure ferritin light chain by induction expression and purification in colon bacillus. Proved by the Westernblot, the protein has good antigenicity.

The invention provides fusion protein, which comprises monomeric ferritin subunit protein connected to porcine epidemic diarrhea virus antigenic protein, which includes porcine epidemic diarrhea virus S protein and/or fragments thereof, and further includes S1 protein, M protein, N protein and/or fragments thereof. The invention further provides nanoparticles containing the fusion protein. The invention further provides a vaccine composition containing the nanoparticles and/or a carrier. The invention further discloses a preparation method of the vaccine composition and an application of the vaccine composition to prepare a medicine for preventing and/or treating porcine epidemic diarrhea virus. The vaccine composition made from the nanoparticles overcomes the technical problem that whole viruses are hard to separate and culture in a process of manufacturing a conventional inactivation vaccine from porcine epidemic diarrhea whole viruses. The nanoparticles can be subjected to massive recombinant expression via genetic engineering technology. The time consumption is short, and the fusion protein is convenient for massive production.

The invention discloses a protein chip used for detecting human ferrum reserve, which belongs to the field of human ferrum nutrition detection. The protein chip comprises a solid-phase carrier, antiserum ferritin monoclonal antibodies, antiserum transferrin receptor monoclonal antibodies and anti-C-reactive-protein monoclonal antibodies, wherein the antiserum ferritin monoclonal antibodies, the antiserum transferring receptor monoclonal antibodies and the anti-C-reactive-protein monoclonal antibodies are distributed on the solid-phase carrier in an array manner, wherein the monoclonal antibodies are fixed on the surface of the solid-phase carrier by covalent bonds, and the solid-phase carrier is finished by hydroformylation. The invention further discloses a detection reagent kit based on the protein chip. Compared with the prior art, the protein chip can detect three indexes of human ferrum reserve simultaneously, is accurate and reliable in results, high in detection specificity, sensitivity and detection speed and stable in detection results. Furthermore, by multi-sample microarray technology, the protein chip is applicable to screening and detecting of massive people, low in blood sample quantity, detection and cost and low in harms to examined people.

A method for the detection of the presence and/or the severity of a liver disease in a patient comprising measuring in an isolated sample TIMP-1 (tissue inhibitor of metalloproteinase I), ferritin, at least one additional parameter selected from the group consisting of A2M (alpha-2-macroglobulin) and PI (prothrombin index) and optionally measuring at least one additional biochemical or clinical parameter and diagnosing the presence and/or severity of a liver disease based on the presence or measured levels of these parameters. The method can be used for monitoring therapeutic treatment of liver fibrosis and staging of liver fibrosis.

A DNA sequence coding for oncofetal ferritin 1 (OFF1) as well as an amino acid sequence encoded by the DNA sequence. Pharmaceutical compositions may be prepared comprising the above-sequences for treating various diseases, for facilitating transplantations and for treating pathological pregnancies.

The invention discloses a novel method for preparing embeddings, which comprises the following steps: placing ferritin solution in a centrifuge tube, adjusting the pH value with sodium hydroxide solution to denature, and stirring; taking natural pigments and dissolving them in ethanol Solution: mix the polyphenol ethanol solution with the above-mentioned ferritin solution, stir at room temperature, adjust the pH value for renaturation, stir in a chromatographic cabinet at 4°C, and dialyze the above-mentioned solution three times to obtain the ferritin natural pigment embedding. Then, the ferritin pigment embedding material and chitosan were mixed in a certain proportion, stirred, statically prepared, and dialyzed in a chromatographic cabinet at 4°C in the dark to obtain the final product. The final product is a new type of embedding material loaded with natural pigment molecules by ferritin/chitosan, which can be used as a new food additive, can also be used to improve medical efficacy, and can also be used as a component in cosmetics, embedding material Ferritin and natural pigments produced after decomposition also have certain biological activity. This product makes full use of the functions of ferritin and natural pigment, and has high practical application and promotion value.

A method for selectively arranging ferritin modified with a peptide, which specifically binds to titanium, to titanium formed on a substrate surface is provided. The method for arranging ferritin of the present invention is characterized in that ferritin is selectively bound on titanium on a substrate by modifying the N-terminal part of ferritin with a peptide which specifically binds to titanium. Also, the method for arranging ferritin of the present invention is characterized in that selectivity for titanium can be markedly improved by adding a nonionic surface activating agent.

Embodiments provide devices, systems and methods for the transdermal delivery of chelated compounds. One embodiment provides a method for the iontophoretic transdermal delivery of a chelated iron complex for the treatment of anemia. A first patch comprising an active electrode and a chelated iron complex is applied to the skin; a second patch containing an electrode is also applied. An electrical current is then delivered to the skin from the active electrode. The chelated complex is transported across the skin via electromotive force from the current, with the iron being substantially chromogenically unreactive with the skin during transport so that there is little or no tattooing of the skin due to the formation of insoluble oxidative products. The complex is then dissociated by phagocytosis or related process to release the iron where it may be bound by transferrin or ferritin and carried to other sites for storage or metabolic use.

The present invention discloses a method for extracting lactoferrin from transgenic lactoferrin rice. Said method includes the following steps: 1), adding water or buffer solution in transgenic lactoferrin rice seed, mixing them, pulverizing to form wet powder; or directly pulverizing transgenic lactoferrin rice seed, then adding water or buffer solution to form wet powder; the buffer solution contains NaCl, whose concentration is less than 0.1 mol/L and whose pH value is 6-9, the temperature of the above-mentioned pulverization process is below 70deg.C, the material-adding ratio of water or buffer solution and transgenic lactoferrin rice seed is 1-10ml/g; and 2), mixing and shaking the above-mentioned wet powder, then making centrifugal separation for 10min, and separating precipitate and supernatant.

The present invention provides nanoparticles and compositions of various constructs that combine meta-stable viral proteins (e.g., RSV F protein) and self-assembling molecules (e.g., ferritin, HSPs) such that the pre-fusion conformational state of these key viral proteins is preserved (and locked) along with the protein self-assembling into a polyhedral shape, thereby creating nanoparticles that are effective vaccine agents. The invention also provides nanoparticles comprising a viral fusion protein, or fragment or variant thereof, and a self-assembling molecule, and immunogenic and vaccine compositions including the same.

The invention discloses a fusing protein and preparing method and application, which is combined of para-insanguinin peptide 1 repeating sequence and human serum albumin, immune globulin, ferritin, steroid connecting protein, transferrin, thyroid connecting protein, alpha-2 macroglobulin and haptoglobin. The invention also provides the coding sequence of fusing protein and carrier and host with the coding chain, which possesses better stability and internal half-life.

It is to provide an inorganic thin film of titanium dioxide or the like which is controlled at the nanoscale and a three-dimensional structure of a functional material such as semiconductor nanoparticles. A three-dimensional structure of an inorganic material is manufactured by introducing onto a surface of an inorganic substrate ferritin presenting on its surface a plurality of inorganic material-binding peptides; binding the ferritin in a monolayer onto the inorganic substrate; introducing an inorganic material onto the ferritin which is bound in a monolayer, while the inorganic material-binding peptides is having a binding and/or biomineralization ability for the inorganic material; forming a biomineral layer utilizing the biomineralization ability of the inorganic material-binding peptides; and subsequently repeating one or more times the steps (a) and (b) of a multilayering operation: (a) introducing onto the biomineral layer thus formed the ferritin having a binding ability to the biomineral layer, and binding the ferritin in a monolayer onto the biomineral layer; (b) introducing the inorganic material onto the surface of the ferritin which is bound in a monolayer, and forming a biomineral layer.